Literature DB >> 34604446

Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay.

Matthew T Keeney1,2,3, Eric K Hoffman1,2, Timothy J Greenamyre1,2, Roberto Di Maio1,2.   

Abstract

Missense mutations in leucine rich-repeat kinase 2 (LRRK2) cause forms of familial Parkinson's disease and have been linked to 'idiopathic' Parkinson's disease. Assessment of LRRK2 kinase activity has been very challenging due to its size, complex structure, and relatively low abundance. A standard in the field to assess LRRK2 kinase activity is to measure the level of substrate phosphorylation (pThr73-Rab10) or autophosphorylation of serine 1292 (i.e., phosphoserine 1292; pS1292). The levels of pS1292 have typically been assessed by western blotting, which limits cellular and anatomical resolution. Here, we describe the method for a novel proximity ligation assay (PLA) that can detect endogenous LRRK2 kinase activity (PLA LRRK2) in situ at cellular and subcellular resolutions. PLA is a fluorescence- or chromogen-based assay that can be used to either (1) detect protein-protein interactions or (2) detect and amplify post-translational modifications on proteins. We used PLA for in situ detection and amplification of LRRK2 autophosphorylation levels at serine 1292. Our findings demonstrate that PLA LRRK2 is a highly sensitive and specific assay that can be used for assessing kinase activity in cultured cells and postmortem tissues.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Fluorescence; LRRK2; Parkinson’s disease; Proximity ligation assay

Year:  2021        PMID: 34604446      PMCID: PMC8443460          DOI: 10.21769/BioProtoc.4140

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  12 in total

1.  The Parkinson Pandemic-A Call to Action.

Authors:  E Ray Dorsey; Bastiaan R Bloem
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

2.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

3.  Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.

Authors:  Kyle B Fraser; Ashlee B Rawlins; Rachel G Clark; Roy N Alcalay; David G Standaert; Nianjun Liu; Andrew B West
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

4.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

5.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

6.  Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson's disease.

Authors:  Meghan L Bucher; Caitlyn W Barrett; Connor J Moon; Amanda D Mortimer; Edward A Burton; J Timothy Greenamyre; Teresa G Hastings
Journal:  NPJ Parkinsons Dis       Date:  2020-11-13

7.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

8.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.

Authors:  Martin Steger; Francesca Tonelli; Genta Ito; Paul Davies; Matthias Trost; Melanie Vetter; Stefanie Wachter; Esben Lorentzen; Graham Duddy; Stephen Wilson; Marco As Baptista; Brian K Fiske; Matthew J Fell; John A Morrow; Alastair D Reith; Dario R Alessi; Matthias Mann
Journal:  Elife       Date:  2016-01-29       Impact factor: 8.140

9.  Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.

Authors:  Belén Fernández; Antonio Jesús Lara Ordóñez; Elena Fdez; Eugénie Mutez; Thomas Comptdaer; Coline Leghay; Alexandre Kreisler; Clémence Simonin; Laurine Vandewynckel; Luc Defebvre; Alain Destée; Séverine Bleuse; Jean-Marc Taymans; Marie-Christine Chartier-Harlin; Sabine Hilfiker
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  3 in total

1.  The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability.

Authors:  Erinc Hallacli; Can Kayatekin; Sumaiya Nazeen; Xiou H Wang; Zoe Sheinkopf; Shubhangi Sathyakumar; Souvarish Sarkar; Xin Jiang; Xianjun Dong; Roberto Di Maio; Wen Wang; Matthew T Keeney; Daniel Felsky; Jackson Sandoe; Aazam Vahdatshoar; Namrata D Udeshi; D R Mani; Steven A Carr; Susan Lindquist; Philip L De Jager; David P Bartel; Chad L Myers; J Timothy Greenamyre; Mel B Feany; Shamil R Sunyaev; Chee Yeun Chung; Vikram Khurana
Journal:  Cell       Date:  2022-06-09       Impact factor: 66.850

2.  NADPH oxidase 2 activity in Parkinson's disease.

Authors:  Matthew T Keeney; Eric K Hoffman; Kyle Farmer; Christopher R Bodle; Marco Fazzari; Alevtina Zharikov; Sandra L Castro; Xiaoping Hu; Amanda Mortimer; Julia K Kofler; Eugenia Cifuentes-Pagano; Patrick J Pagano; Edward A Burton; Teresa G Hastings; J Timothy Greenamyre; Roberto Di Maio
Journal:  Neurobiol Dis       Date:  2022-05-13       Impact factor: 7.046

3.  Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.

Authors:  Belén Fernández; Vinita G Chittoor-Vinod; Jillian H Kluss; Kaela Kelly; Nicole Bryant; An Phu Tran Nguyen; Syed A Bukhari; Nathan Smith; Antonio Jesús Lara Ordóñez; Elena Fdez; Marie-Christine Chartier-Harlin; Thomas J Montine; Mark A Wilson; Darren J Moore; Andrew B West; Mark R Cookson; R Jeremy Nichols; Sabine Hilfiker
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.